Piu Chan
Plus aucun poste en cours
Profil
Piu Chan is the founder of XingImaging LLC, which was founded in 2018.
Anciens postes connus de Piu Chan
| Sociétés | Poste | Fin |
|---|---|---|
XingImaging LLC (Connecticut)
 XingImaging LLC (Connecticut) Miscellaneous Commercial ServicesCommercial Services XingImaging LLC is a full-service CRO company based in Madison, CT. XingImaging provides the capability for PET radiotracer production and PET acquisition, supporting multi-center trials in the US and China, which require PET for study eligibility, disease evaluation, and treatment efficacy. The PET production facilities in the XingImaging network are located at class-4 hospitals in China, and the company is currently expanding to other regions. XingImaging is committed to producing radiotracers to support clinical trials in Alzheimer's disease. The company was founded in 2018 by Gilles Tamagnan, Piu Chan, John Seibyl, and Kenneth Marek, with Gilles Tamagnan serving as the CEO since then. The company has established a network of radiopharmaceutical tracer production and imaging centers for PET acquisition and image analysis, utilizing the most advanced neuroimaging tracer compounds available to be used in AD clinical trials. | Fondateur | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
XingImaging LLC (Connecticut)
XingImaging LLC (Connecticut) Miscellaneous Commercial ServicesCommercial Services XingImaging LLC is a full-service CRO company based in Madison, CT. XingImaging provides the capability for PET radiotracer production and PET acquisition, supporting multi-center trials in the US and China, which require PET for study eligibility, disease evaluation, and treatment efficacy. The PET production facilities in the XingImaging network are located at class-4 hospitals in China, and the company is currently expanding to other regions. XingImaging is committed to producing radiotracers to support clinical trials in Alzheimer's disease. The company was founded in 2018 by Gilles Tamagnan, Piu Chan, John Seibyl, and Kenneth Marek, with Gilles Tamagnan serving as the CEO since then. The company has established a network of radiopharmaceutical tracer production and imaging centers for PET acquisition and image analysis, utilizing the most advanced neuroimaging tracer compounds available to be used in AD clinical trials. | Commercial Services |
